2643 Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (UBC): Updated clinical and translational findings of an open-label, single group, phase 2 study. (September 2015) - Necchi, A.; Giannatempo, P.; Mariani, L.; Raggi, D.; Nicolai, N.; Piva, L.; Biasoni, D.; Catanzaro, M.; Torelli, T.; Stagni, S.; Calareso, G.; Togliardi, E.; et al.